var data={"title":"Simvastatin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Simvastatin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6956?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=simvastatin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Simvastatin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=simvastatin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Simvastatin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221302\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>FloLipid;</li>\n      <li>Zocor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50644108\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Zocor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221350\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antilipemic Agent, HMG-CoA Reductase Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221307\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Doses should be individualized according to the baseline LDL-cholesterol levels, the recommended goal of therapy, and the patient's response; adjustments should be made at intervals of 4 weeks or more; doses may need adjusted based on concomitant medications.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note: Dosing limitation: Simvastatin 80 mg is limited to patients that have been taking this dose for &gt;12 consecutive months without evidence of myopathy and are not currently taking or beginning to take a simvastatin dose-limiting or contraindicated interacting medication.</b> If patient is unable to achieve low-density lipoprotein-cholesterol (LDL-C) goal using the 40 mg dose of simvastatin, increasing to 80 mg dose is not recommended. Instead, switch patient to an alternative LDL-C-lowering treatment providing greater LDL-C reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Homozygous familial hypercholesterolemia:</b> Oral: 40 mg once daily in the evening</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Prevention of cardiovascular events (also see ACC/AHA Blood Cholesterol Guideline recommendations), hyperlipidemias:</b> Oral: Initial: 10 to 20 mg once daily in the evening; range: 5 to 40 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Patients requiring only moderate reduction of LDL-C:</i> May be started at 5 to 10 mg once daily in the evening; adjust to achieve recommended LDL-C goal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Patients requiring reduction of &gt;40% of LDL-C:</i> May be started at 40 mg once daily in the evening; adjust to achieve recommended LDL-C goal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Patients with CHD or at high risk for cardiovascular events (patients with diabetes, PVD, history of stroke or other cerebrovascular disease):</i> Dosing should be started at 40 mg once daily in the evening; start simultaneously with diet therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Prevention of cardiovascular disease/reduce the risk of ASCVD: </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>ACC/AHA Blood Cholesterol Guideline recommendations (ACC/AHA [Stone 2013]):</b> Adults &ge;21 years:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Primary prevention:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>LDL-C &ge;190 mg/dL</i>: High intensity therapy necessary; use alternate statin therapy (eg, atorvastatin or rosuvastatin)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Type 1 or 2 diabetes and age 40 to 75 years</i>: Moderate intensity therapy: 20 to 40 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Type 1 or 2 diabetes, age 40 to 75 years, and an estimated 10-year ASCVD risk &ge;7.5%</i>: High intensity therapy necessary; use alternate statin therapy (eg, atorvastatin or rosuvastatin)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Age 40 to 75 years and an estimated 10-year ASCVD risk &ge;7.5%</i>: Moderate to high intensity therapy: 20 to 40 mg once daily or consider using high intensity statin therapy (eg, atorvastatin or rosuvastatin)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Secondary prevention:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patient has clinical ASCVD (eg, coronary heart disease, stroke/TIA, or peripheral arterial disease presumed to be of atherosclerotic origin) or is post-CABG (AHA [Kulik 2015]) <b>and</b>:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Age &le;75 years</i>: High intensity therapy necessary; use alternate statin therapy (eg, atorvastatin or rosuvastatin)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Age &gt;75 years or not a candidate for high intensity therapy</i>: Moderate intensity therapy: 20 to 40 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>NLA Dyslipidemia Recommendations (NLA [Jacobson 2015]): </b>Adults &ge;20 years:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Primary or secondary prevention: Note: </b>Treatment initiation using either moderate- or high-intensity statin therapy is recommended in qualifying patients based on ASCVD risk assessment criteria <b>and</b> baseline non-HDL-C and LDL-C values. Dosage should be individualized based on patient characteristics, tolerance to therapy, and with consideration for non-HDL-C and LDL-C treatment goals.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate-intensity therapy (30% to 50% reduction of LDL-C generally): 20 to 40 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">High-intensity therapy (&ge;50% reduction of LDL-C generally): Use alternate statin therapy (eg, atorvastatin or rosuvastatin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>US Preventive Services Task Force Recommendations (USPSTF 2016</b>\n      <b>): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Primary prevention:</b> Age 40 to 75 years, no history of CVD, with &ge;1 CVD risk factor (dyslipidemia, diabetes, hypertension, or smoking), and calculated 10-year CVD event risk of &ge;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Low to moderate intensity therapy: 10 to 40 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> These recommendations do not pertain to patients with very high CVD risk factors (eg, LDL &gt;190 mg/dL, familial hypercholesterolemia) (were excluded from primary prevention trials); use clinical judgement in the treatment of these patients. In patients with a calculated 10-years CVD event risk of 7.5% to 10%, may consider use of a statin based on patient characteristics.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment for simvastatin with concomitant medications:</b> <b>Note:</b> Patients currently tolerating and requiring a dose of simvastatin 80 mg who require initiation of an interacting drug with a dose cap for simvastatin should be switched to an alternative statin with less potential for drug-drug interaction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Amiodarone, amlodipine, or ranolazine:</i> Simvastatin dose should <b>not</b> exceed 20 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Diltiazem, dronedarone, or verapamil:</i> Simvastatin dose should <b>not</b> exceed 10 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Lomitapide:</i> Reduce simvastatin dose by 50% when initiating lomitapide. Simvastatin dose should not exceed 20 mg/day (or 40 mg daily for those who previously tolerated simvastatin 80 mg daily for &ge;1 year without evidence of muscle toxicity).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment in Chinese patients on niacin doses &ge;1 g/day:</b> Use caution with simvastatin doses exceeding 20 mg/day; because of an increased risk of myopathy, do not administer simvastatin 80 mg concurrently.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221328\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=simvastatin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Simvastatin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>HeFH:</b> Oral: Children and Adolescents 10 to 17 years (females &gt;1 year postmenarche): Initial: 10 mg once daily in the evening; range: 10 to 40 mg/day (maximum: 40 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment with concomitant medications:</b> With concomitant amiodarone, amlodipine, diltiazem, dronedarone, lomitapide, ranolazine, or verapamil: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Doses should be individualized according to the baseline LDL-cholesterol levels, the recommended goal of therapy, and the patient's response; adjustments should be made at intervals of 4 weeks or more; doses may need adjusted based on concomitant medications</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221308\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221309\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild to moderate impairment: No dosage adjustment necessary; simvastatin does not undergo significant renal excretion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment: Initial: 5 mg once daily with close monitoring.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22553685\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Contraindicated in active liver disease or in patients with unexplained persistent elevations of serum transaminases.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22888200\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Severe muscle symptoms or fatigue:</b> Promptly discontinue use; evaluate CPK, creatinine, and urinalysis for myoglobinuria (Stone 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mild to moderate muscle symptoms:</b> Discontinue use until symptoms can be evaluated; evaluate patient for conditions that may increase the risk for muscle symptoms (eg, hypothyroidism, reduced renal or hepatic function, rheumatologic disorders such as polymyalgia rheumatica, steroid myopathy, vitamin D deficiency, or primary muscle diseases). Upon resolution, resume the original or lower dose of simvastatin. If muscle symptoms recur, discontinue simvastatin use. After muscle symptom resolution, may then use a low dose of a different statin; gradually increase if tolerated. In the absence of continued statin use, if muscle symptoms or elevated CPK continues after 2 months, consider other causes of muscle symptoms. If determined to be due to another condition aside from statin use, may resume statin therapy at the original dose (Stone 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221278\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">FloLipid: 20 mg/5 mL (150 mL); 40 mg/5 mL (150 mL) [contains ethylparaben, methylparaben, propylene glycol, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zocor: 5 mg, 10 mg, 20 mg, 40 mg, 80 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg, 20 mg, 40 mg, 80 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221263\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221282\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension: Administer in the evening on an empty stomach. Shake well for at least 20 seconds before administering dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets: Administered without regard to meals. Administer in the evening for maximal efficacy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221281\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hyperlipidemias:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dysbetalipoproteinemia:</b> Reduce elevated triglycerides (TG) and very low-density lipoprotein cholesterol (VLDL-C) in patients with primary dysbetalipoproteinemia (Fredrickson type III)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Heterozygous familial and nonfamilial hypercholesterolemia and mixed dyslipidemia:</b> To reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apo B), and TG, and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Heterozygous familial hypercholesterolemia (HeFH) in adolescents:</b> To reduce total-C, LDL-C, and apo B levels in boys and postmenarche girls 10 to 17 years of age with heterozygous familial hypercholesterolemia with either LDL-C &ge;190 mg/dL, LDL-C &ge;160 mg/dL with positive family history of premature cardiovascular disease (CVD), or LDL-C &ge;160 mg/dL with two or more other CVD risk factors</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Homozygous familial hypercholesterolemia:</b> To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (eg, LDL apheresis) or if such treatments are unavailable</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypertriglyceridemia:</b> To reduce elevated serum triglyceride levels in patients with hypertriglyceridemia (Fredrickson type IV)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Has not been studied in conditions where the major lipid abnormality is elevation of chylomicrons (Fredrickson types I and V)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of cardiovascular events:</b> To reduce the risk of nonfatal MI, stroke, and total mortality; and to reduce the need for coronary/non-coronary revascularization procedures in patients at high risk of coronary events (eg, patients with coronary heart disease, diabetes, PVD, history of stroke or other cerebrovascular disease)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Guideline recommendations: </i></b>Primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) to reduce the risk of ASCVD in select adult patients (ACC/AHA [Stone 2013]; ADA 2018a; NLA [Jacobson 2015]; USPSTF 2016). Refer to respective guideline for specific recommendations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50324443\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Cardiac risk reduction for noncardiac surgery (perioperative therapy); Noncardioembolic stroke/Transient ischemic attack (secondary prevention)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221358\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Simvastatin may be confused with atorvaSTATin, nystatin, pitavastatin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Zocor may be confused with Cozaar, Lipitor, Zoloft, ZyrTEC</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cardin [Poland] may be confused with Cardem brand name for celiprolol [Spain]; Cardene brand name for nicardipine [US, Great Britain, Netherlands]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221270\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Atrial fibrillation (6%), edema (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache (3% to 7%), vertigo (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Eczema (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain (7%), constipation (2% to 7%), gastritis (5%), nausea (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Cystitis (interstitial; Huang 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased transaminases (&gt;3 x ULN; 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Increased CPK (&gt;3 x normal; 5%), myalgia (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Upper respiratory infections (9%), bronchitis (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Alopecia, amnesia (reversible), anaphylaxis, anemia, angioedema, arthralgia, arthritis, chills, cognitive impairment (reversible), confusion (reversible), depression, dermatomyositis, diabetes mellitus (new onset), diarrhea, dizziness, dryness of skin/mucous membranes, dysgeusia (Tuccori 2011), dyspepsia, dyspnea, elevated glycosylated hemoglobin (HbA<sub>1c</sub>), eosinophilia, erythema multiforme, fever, flatulence, flushing, hemolytic anemia, hepatic failure, hepatitis, hypersensitivity reaction, increased alkaline phosphatase, increased blood glucose, increased ESR, increased GGT, increased serum alkaline phosphatase, jaundice, leukopenia, malaise, memory impairment (reversible), muscle cramps, nail changes, nodules, pancreatitis, paresthesia, peripheral neuropathy, polymyalgia rheumatica, positive ANA, pruritus, purpura, rhabdomyolysis, skin discoloration, skin photosensitivity, skin rash, Stevens-Johnson syndrome, systemic lupus erythematosus-like syndrome, thrombocytopenia, toxic epidermal necrolysis, ulcerative colitis, urticaria, vasculitis, vomiting, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221285\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to simvastatin or any component of the formulation; active liver disease; unexplained persistent elevations of serum transaminases; concomitant use of strong CYP3A4 inhibitors (eg, clarithromycin, erythromycin, itraconazole, ketoconazole, nefazodone, posaconazole, voriconazole, protease inhibitors [including boceprevir and telaprevir], telithromycin, cobicistat-containing products), cyclosporine, danazol, and gemfibrozil; pregnancy or women who may become pregnant; breastfeeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221267\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes mellitus: Increases in HbA<sub>1c</sub> and fasting blood glucose have been reported; however, the benefits of statin therapy far outweigh the risk of dysglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Persistent elevations in serum transaminases have been reported; upon dose reduction, drug interruption, or discontinuation, transaminase levels returned to or near pretreatment levels. Postmarketing reports of fatal and nonfatal hepatic failure have been reported and are rare. If serious hepatotoxicity with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment, interrupt therapy promptly. If an alternate etiology is not identified, do not restart simvastatin. Liver enzyme tests should be obtained at baseline and as clinically indicated. Ethanol may enhance the potential of adverse hepatic effects; instruct patients to avoid excessive ethanol consumption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myopathy/rhabdomyolysis: Rhabdomyolysis with or without acute renal failure secondary to myoglobinuria and/or myopathy has been reported; patients should be monitored closely. This risk is dose-related and is increased with high doses of simvastatin (80 mg). Concomitant use of strong CYP3A4 inhibitors (eg, clarithromycin, erythromycin, itraconazole, ketoconazole, nefazodone, posaconazole, voriconazole, protease inhibitors [including boceprevir and telaprevir], telithromycin, cobicistat-containing products), cyclosporine, danazol, and gemfibrozil is contraindicated due to increased risk of myopathy. Use with caution in patients with uncontrolled hypothyroidism, patients taking other drugs associated with myopathy (eg, colchicine), &ge;65 years of age, and women; these patients are predisposed to myopathy. Immune-mediated necrotizing myopathy (IMNM) associated with HMG-CoA reductase inhibitors use has also been reported. Patients should be instructed to report unexplained muscle pain, tenderness, weakness, or brown urine, particularly if accompanied by malaise or fever. Discontinue therapy if markedly elevated CPK levels occur or myopathy is diagnosed/suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment and/or ethanol use: Use with caution in patients who consume large amounts of ethanol or have a history of liver disease. Use is contraindicated with active liver disease and with unexplained transaminase elevations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with severe renal impairment (creatinine clearance not defined). Initial dosage adjustment necessary; monitor closely. Patients with renal impairment are predisposed to myopathy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special Populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chinese patients: Increased risk for myopathy in Chinese patients; use with caution. Do not use high dose simvastatin (80 mg) if concurrently taking niacin &ge;1 g/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in patients &ge;65 years of age; these patients are predisposed to myopathy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical patients: The manufacturer recommends temporary discontinuation for elective major surgery, acute medical or surgical conditions, or in any patient experiencing an acute or serious condition predisposing to renal failure (eg, sepsis, hypotension, trauma, uncontrolled seizures; severe metabolic, endocrine, or electrolyte disorders, or uncontrolled epilepsy). Based on current research and clinical guidelines, HMG-CoA reductase inhibitors should be continued in the perioperative period. Postoperative discontinuation of statin therapy is associated with an increased risk of cardiac morbidity and mortality (ACC/AHA [Fleisher 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Drug therapy should be only one component of multiple risk factor intervention in patients at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. In patients with CHD or multiple risk factors for CHD, initiate therapy simultaneously with diet.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperlipidemia: Secondary causes of hyperlipidemia should be ruled out prior to therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221344\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major), OATP1B1/SLCO1B1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221272\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9923&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acipimox: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: May increase the serum concentration of Simvastatin. Management: Consider using a non-interacting statin (pravastatin) in patients on amiodarone. If combined, limit the simvastatin dose to 20 mg daily and monitor for evidence of simvastatin toxicities (eg, myalgia, liver function test elevations, rhabdomyolysis).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AmLODIPine: May increase the serum concentration of Simvastatin. Management: Avoid the concurrent use of amlodipine with simvastatin when possible.  If used together, avoid doses of simvastatin greater than 20 mg/day (for adults).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azithromycin (Systemic): May enhance the myopathic (rhabdomyolysis) effect of Simvastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bezafibrate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). More specifically, bezafibrate may increase the serum concentration of fluvastatin Management: Monitor patients closely for myopathy with concomitant use of bezafibrate and HMG-CoA reductase inhibitors. Concomitant use is contraindicated in patients predisposed to myopathy and alternative therapy should be considered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May increase the serum concentration of Simvastatin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of Simvastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Management: Avoid the use of HMG-CoA reductase inhibitors and ciprofibrate if possible. If concomitant therapy is considered, benefits should be carefully weighed against the risks, and patients should be monitored closely for signs/symptoms of muscle toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clarithromycin: May increase the serum concentration of Simvastatin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May increase the serum concentration of Simvastatin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Simvastatin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyproterone: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Avoid use of statins metabolized by CYP3A4 (eg, simvastatin) and consider avoiding fluvastatin as well in patients receiving high dose cyproterone (300 mg/day). Consider use of pravastatin, rosuvastatin, or pitavastatin if statin therapy is needed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Simvastatin may enhance the anticoagulant effect of Dabigatran Etexilate.  Management: Consider an alternative HMG-CoA reductase inhibitor (statin) in patients taking dabigatran who require statin therapy. If used together, monitor patients closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daclatasvir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Danazol: May increase the serum concentration of Simvastatin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DAPTOmycin: HMG-CoA Reductase Inhibitors (Statins) may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased.  Management: Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to daptomycin.  If used together, regular (i.e., at least weekly) monitoring of CPK concentrations is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DilTIAZem: Simvastatin may increase the serum concentration of DilTIAZem. DilTIAZem may increase the serum concentration of Simvastatin.  Management: Avoid concurrent use of diltiazem with simvastatin when possible.  If used together, limit adult doses to simvastatin 10 mg/day and diltiazem 240 mg/day; avoid Simcor (simvastatin/niacin) because fixed simvastatin doses exceed the maximum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronedarone: May increase the serum concentration of Simvastatin. Management: Limit simvastatin to a max of 10 mg/day (in adults). Increase monitoring for signs of simvastatin toxicity (e.g., myositis, rhabdomyolysis).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease the serum concentration of Simvastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Elbasvir: May increase the serum concentration of Simvastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erythromycin (Systemic): May increase the serum concentration of Simvastatin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eslicarbazepine: May decrease the serum concentration of Simvastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etravirine: May decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins). This applies to atorvastatin, lovastatin and simvastatin. Conversely, levels of fluvastatin may be increased. Management: Dose adjustment of the HMG-CoA reductase inhibitor may be warranted. No interaction is expected with rosuvastatin, pravastatin, or pitavastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fenofibrate and Derivatives: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Simvastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Specifically, the risk for muscle toxicities, including rhabdomyolysis may be significantly increased. Management: Avoid concurrent use whenever possible. Use is listed as contraindicated in product characteristic summaries in several countries, although UK labeling suggests that use could be considered under exceptional circumstances and with close supervision.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gemfibrozil: May enhance the myopathic (rhabdomyolysis) effect of Simvastatin. Gemfibrozil may increase the serum concentration of Simvastatin. Concentrations of the active simvastatin acid metabolite may also be increased by gemfibrozil.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glecaprevir and Pibrentasvir: May increase the serum concentration of Simvastatin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May increase the serum concentration of Simvastatin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grazoprevir: May increase the serum concentration of Simvastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Green Tea: May increase the serum concentration of Simvastatin. Specifically, Simvastatin lactone concentrations may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: May decrease the metabolism of Simvastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: HMG-CoA Reductase Inhibitors (Statins) may decrease the serum concentration of Lanthanum.  Management: Administer HMG-CoA reductase inhibitors at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lercanidipine: May increase the serum concentration of Simvastatin. Management: Administer lercanidipine in the morning and simvastatin in the evening in patients receiving these drugs in combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Letermovir: May increase the serum concentration of Simvastatin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: May increase the serum concentration of Simvastatin. Management: Reduce the recommended simvastatin dose by 50%. Generally, limit the maximum adult simvastatin dose to 20 mg/day. A 40 mg/day dose can be considered in patients who previously received 80 mg/day for at least a year without evidence of muscle toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of Simvastatin. Management: Avoid simvastatin during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Niacin: May enhance the myopathic (rhabdomyolysis) effect of Simvastatin. Niacin may increase the serum concentration of Simvastatin. Management: Use of simvastatin 80 mg with niacin should be avoided and simvastatin doses over 20 mg/day should be used cautiously in Chinese patients; some non-US labeling state this combination is not recommended in any Asian patients.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Niacinamide: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: HMG-CoA Reductase Inhibitors (Statins) may enhance the hepatotoxic effect of PAZOPanib. Specifically, the risk for increased serum transaminase concentrations may be increased.  Management: Simvastatin is specifically implicated in the interaction. There is a lack of data regarding risk with other statins, but caution appears warranted with any statins. Atorvastatin should be avoided due to P-gp inhibition.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protease Inhibitors: May increase the serum concentration of Simvastatin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Consider using a lower starting dose and lower maintenance/maximum doses of atorvastatin, simvastatin, or lovastatin when used together with quinine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raltegravir: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of Simvastatin. Management: Avoid the concurrent use of ranolazine with simvastatin when possible. If used together, avoid doses of simvastatin greater than 20 mg/day.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Red Yeast Rice: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Repaglinide: HMG-CoA Reductase Inhibitors (Statins) may increase the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Consider use of noninteracting antilipemic agents (note: pitavastatin concentrations may increase with rifamycin treatment).  Monitor for altered HMG-CoA reductase inhibitor effects. Rifabutin and fluvastatin, or possibly pravastatin, may pose lower risk.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rupatadine: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Specifically, the risk for increased CPK and/or other muscle toxicities may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of Simvastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May increase the metabolism of HMG-CoA Reductase Inhibitors (Statins). Management: Consider avoiding the concomitant administration of St Johns Wort with interacting HMG-CoA reductase inhibitors in order to avoid the potential for decreased antilipemic effects. Monitor for decreased effects during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of Simvastatin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telithromycin: May increase the serum concentration of Simvastatin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ticagrelor: May increase the serum concentration of Simvastatin. Management: Avoid using doses of simvastatin greater than 40 mg/day with ticagrelor.  This specific recommendation is found in the U.S. prescribing information but not in the Canadian product monograph.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trabectedin: HMG-CoA Reductase Inhibitors (Statins) may enhance the myopathic (rhabdomyolysis) effect of Trabectedin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verapamil: May increase the serum concentration of Simvastatin. Management: Avoid concurrent use of verapamil with simvastatin when possible.   If used together, limit adult maximum simvastatin dose to 10 mg/day, and avoid Simcor (simvastatin/niacin) because fixed simvastatin doses in the product exceed this maximum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): HMG-CoA Reductase Inhibitors (Statins) may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voxilaprevir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Use the lowest statin dose possible if combined with voxilaprevir and monitor patients for increased statin effects/toxicities. Avoid concomitant use of voxilaprevir with rosuvastatin or pitavastatin, and limit pravastatin doses to 40 mg daily.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221299\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Simvastatin serum concentration may be increased when taken with grapefruit juice. Management: Avoid combination.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221274\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1792946\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Studies in pregnant women have shown evidence of fetal abnormalities and use is contraindicated in women who are or may become pregnant. There are reports of congenital anomalies following maternal use of HMG-CoA reductase inhibitors in pregnancy; however, maternal disease, differences in specific agents used, and the low rates of exposure limit the interpretation of the available data (Godfrey 2012; Lecarpentier 2012). Cholesterol biosynthesis may be important in fetal development; serum cholesterol and triglycerides increase normally during pregnancy. The discontinuation of lipid lowering medications temporarily during pregnancy is not expected to have significant impact on the long term outcomes of primary hypercholesterolemia treatment.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use of simvastatin is contraindicated in pregnancy. Because they are potentially teratogenic, the ADA Diabetes guidelines recommends avoiding use of HMG-CoA reductase inhibitors in sexually active women of childbearing age who are not using reliable contraception (ADA 2018b). If treatment of dyslipidemias is needed in pregnant women or in women of reproductive age, other agents are preferred (Berglund 2012; Stone 2013). The manufacturer recommends administration to women of childbearing potential only when conception is highly unlikely and patients have been informed of potential hazards.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221288\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if simvastatin is present into breast milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is contraindicated by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F802418\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Generally, patients should be placed on a standard cholesterol-lowering diet and other lifestyle modifications for 3 to 6 months prior to the initiation of drug therapy. The diet should be continued during drug therapy. However, for patients with advanced risk factors (eg, known coronary heart disease), drug therapy may be initiated concurrently with diet modification. Simvastatin serum concentration may be increased when taken with grapefruit juice; avoid concurrent intake of grapefruit juice.</p>\n    <p style=\"text-indent:0em;\">Red yeast rice contains variable amounts of several compounds that are structurally similar to HMG-CoA reductase inhibitors, primarily monacolin K (or mevinolin) which is structurally identical to lovastatin; concurrent use of red yeast rice with HMG-CoA reductase inhibitors may increase the incidence of adverse and toxic effects (Lapi 2008; Smith 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221276\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>\n        <i>2013 ACC/AHA Blood Cholesterol Guideline recommendations (Stone 2013):</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lipid panel (total cholesterol, HDL, LDL, triglycerides):</b> Baseline lipid panel; fasting lipid profile within 4 to 12 weeks after initiation or dose adjustment and every 3 to 12 months (as clinically indicated) thereafter. If 2 consecutive LDL levels are &lt;40 mg/dL, consider decreasing the dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hepatic transaminase levels:</b> Baseline measurement of hepatic transaminase levels (ie, ALT); measure hepatic function if symptoms suggest hepatotoxicity (eg, unusual fatigue or weakness, loss of appetite, abdominal pain, dark-colored urine or yellowing of skin or sclera) during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>CPK: </b>CPK should not be routinely measured. Baseline CPK measurement is reasonable for some individuals (eg, family history of statin intolerance or muscle disease, clinical presentation, concomitant drug therapy that may increase risk of myopathy). May measure CPK in any patient with symptoms suggestive of myopathy (pain, tenderness, stiffness, cramping, weakness, or generalized fatigue).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Evaluate for new-onset diabetes mellitus during therapy; if diabetes develops, continue statin therapy and encourage adherence to a heart-healthy diet, physical activity, a healthy body weight, and tobacco cessation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If patient develops a confusional state or memory impairment, may evaluate patient for nonstatin causes (eg, exposure to other drugs), systemic and neuropsychiatric causes, and the possibility of adverse effects associated with statin therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Manufacturer's labeling:</i></b> Liver enzyme tests at baseline and repeated when clinically indicated. Measure CPK when myopathy is being considered or may measure CPK periodically in high risk patients (eg, drug-drug interaction). Lipid panel should be analyzed after 4 weeks of therapy and periodically thereafter.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49055596\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Treatment goals: </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]):</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Low risk (no risk factors):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-HDL-C: &lt;160 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">LDL-C: &lt;130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ApoB: No recommendation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Moderate (&le;2 risk factors; 10-year risk &lt;10%) or high risk (diabetes; CKD stage 3 to 4; &ge;2 risk factors and 10-year risk 10% to 20%):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-HDL-C: &lt;130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">LDL-C: &lt;100 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Apo B: &lt;90 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Very high risk (ACS; carotid/peripheral artery disease; diabetes or CKD stage 3 to 4 with &ge;1 risk factors; HeFH; 10-year risk &gt;20%):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-HDL-C: &lt;100 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">LDL-C: &lt;70 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Apo B: &lt;80 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Extreme risk (progressive atherosclerotic CVD after achieving LDL</i>\n      <i>&#8208;C &lt;70 mg/dL; CVD and diabetes, CKD stage 3 to 4, or HeFH; history of premature atherosclerotic CVD (&lt;55 years [males]; &lt;65 years [females]):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-HDL-C: &lt;80 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">LDL-C: &lt;55 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Apo B: &lt;70 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>National Lipid Association Dyslipidemia recommendations (NLA [Jacobson 2015]):</b> Adults &ge;20 years:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Low-, moderate-, or high-risk patient categories: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-HDL-C &lt;130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">LDL-C &lt;100 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Apo B &lt;90 mg/dL (Apo B is a secondary, optional target of treatment for patients that have achieved treatment goals for non-HDL-C and LDL-C)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note: </b>For patients with diabetes plus 1 major ASCVD risk factor (ie, <i>high risk </i>category), treating to a non-HDL-C goal of &lt;100 mg/dL (LDL-C of &lt;70 mg/dL) may be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Very high-risk patient category:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-HDL-C &lt;100 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">LDL-C &lt;70 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Apo B &lt;80 mg/dL (Apo B is a secondary, optional target of treatment for patients that have achieved treatment goals for non-HDL-C and LDL-C)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221266\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Simvastatin is a methylated derivative of lovastatin that acts by competitively inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis. In addition to the ability of HMG-CoA reductase inhibitors to decrease levels of high-sensitivity C-reactive protein (hsCRP), they also possess pleiotropic properties including improved endothelial function, reduced inflammation at the site of the coronary plaque, inhibition of platelet aggregation, and anticoagulant effects (de Denus 2002; Ray 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221284\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: &gt;3 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LDL-C reduction: 20 to 40 mg/day: 35% to 41% (for each doubling of this dose, LDL-C is lowered ~6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Average HDL-C increase: 5% to 15% </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Average triglyceride reduction: 7% to 30% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Although 85% is absorbed following administration, &lt;5% reaches the general circulation due to an extensive first-pass effect</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~95% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via CYP3A4; extensive first-pass effect </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: &lt;5% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Unknown </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: 1.3 to 2.4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (60%); urine (13%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221287\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Simvastatin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (90): $189.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (90): $253.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (90): $441.37</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (90): $441.37</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (90): $441.37</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Zocor Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $124.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $166.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $290.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (30): $290.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (30): $290.16</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221289\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Antex (PY);</li>\n      <li>Avastinee (HK);</li>\n      <li>Bestatin (TH);</li>\n      <li>Biosim (IN);</li>\n      <li>Cholestat (ID);</li>\n      <li>Clinfar (BR);</li>\n      <li>Colesken (MX);</li>\n      <li>Corstat (HK);</li>\n      <li>Cotritev (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Covastin (HK, MY, SG);</li>\n      <li>Decrelip (PY);</li>\n      <li>Ecuvas (EC);</li>\n      <li>Esvat (ID);</li>\n      <li>Ethicol (ID);</li>\n      <li>Eucor (TH);</li>\n      <li>Forcad (PH);</li>\n      <li>Husimba (KR);</li>\n      <li>Ifistatin (SG);</li>\n      <li>Klonastin (AR);</li>\n      <li>Lesvatin (ID);</li>\n      <li>Lipaco (MY);</li>\n      <li>Lipecor (KR);</li>\n      <li>Lipex (AU, HR, NZ);</li>\n      <li>Lipidoff (TW);</li>\n      <li>Lipinorm (ID);</li>\n      <li>Liponorm (IT);</li>\n      <li>Lipovas (JP);</li>\n      <li>Lochol (TH);</li>\n      <li>Lodales (FR);</li>\n      <li>Luoqi (CN);</li>\n      <li>Mersivas (ID);</li>\n      <li>Nimicor (CL);</li>\n      <li>Nor-Vastina (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Orovas (PH);</li>\n      <li>Priacin (SG);</li>\n      <li>Pulsar AT (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Pusarat (MX);</li>\n      <li>Ransim (AU);</li>\n      <li>Rechol (ID);</li>\n      <li>Recol (BD);</li>\n      <li>Rezostatin (TW);</li>\n      <li>Roco (KR);</li>\n      <li>Simaspen (ZA);</li>\n      <li>Simastin (BD);</li>\n      <li>Simaz (LK);</li>\n      <li>Simbado (ID);</li>\n      <li>Simchol (ID);</li>\n      <li>Simlo (MX, ZW);</li>\n      <li>Simovil (IL);</li>\n      <li>Simplaqor (MX);</li>\n      <li>Simstat (UA);</li>\n      <li>SimStatin (NZ);</li>\n      <li>Simtan (IE);</li>\n      <li>Simtin (SG);</li>\n      <li>Simva (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Simvacor (IL, KW, LV, MY, SG);</li>\n      <li>Simvahex (PH);</li>\n      <li>Simvahexal (TW);</li>\n      <li>Simvalord (KR);</li>\n      <li>Simvar (AU);</li>\n      <li>Simvart (KR);</li>\n      <li>Simvast (AE, BH, ET, QA);</li>\n      <li>Simvastan (KR);</li>\n      <li>Simvata (KR);</li>\n      <li>Simvatin (AE, BH, CY, EG, IQ, IR, JO, KR, KW, LB, LY, OM, QA, SA, SY, YE, ZA);</li>\n      <li>Simvaxon (IL);</li>\n      <li>Simvor (LK, TH, VN);</li>\n      <li>Sinty (TW);</li>\n      <li>Sinvacor (IT);</li>\n      <li>Sivas (KR);</li>\n      <li>Sivastin (IT);</li>\n      <li>Statin (CO);</li>\n      <li>Stavid (ET, MY);</li>\n      <li>Torio (TH);</li>\n      <li>Tulip (MX);</li>\n      <li>Valemia (ID);</li>\n      <li>Vascor (MY, SG);</li>\n      <li>Vasilip (HK);</li>\n      <li>Vasotenal (PE);</li>\n      <li>Vastin (BD);</li>\n      <li>Vidastat (PH);</li>\n      <li>Zeid (MX);</li>\n      <li>Zetina (EC);</li>\n      <li>Zimmex (TH);</li>\n      <li>Zimstat (AU);</li>\n      <li>Zocor (AE, AR, AU, BB, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CO, CR, CY, CZ, DE, DK, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, GY, HK, HN, HR, HU, ID, IE, IT, JM, JO, KE, KR, KW, LB, LK, LR, LU, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, PA, PE, PH, PK, PL, PT, QA, RO, SA, SC, SD, SK, SL, SN, SR, SV, TH, TN, TR, TT, TW, TZ, UG, UY, VE, VN, ZM, ZW);</li>\n      <li>Zocor HP (PH);</li>\n      <li>Zocord (AT, SE);</li>\n      <li>Zokor (UA);</li>\n      <li>Zorced (MX);</li>\n      <li>Zostin (BD);</li>\n      <li>Zovast (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 9. Cardiovascular disease and risk management: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018a;41(suppl 1): S86-S104. doi: 10.2337/dc18-S009.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/29222380/pubmed\" target=\"_blank\" id=\"29222380\">29222380</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29222384\"></a>American Diabetes Association (ADA). 13. Management of diabetes in pregnancy: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018b;41(suppl 1):S137-S143. doi: 10.2337/dc18-S013.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/29222384/pubmed\" target=\"_blank\" id=\"29222384\">29222384</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berglund L, Brunzell JD, Goldberg AC, et al, &ldquo;Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline,&rdquo; <i>J Clin Endocrinol Metab</i>, 2012, 97(9):2969-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/22962670/pubmed\" target=\"_blank\" id=\"22962670\">22962670</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, &quot;Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada,&quot; <i>Can J Diabetes</i>, 2013, 35(Suppl 1):1-212.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Castro C and Gourley M, &quot;Diagnosis and Treatment of Inflammatory Myopathy: Issues and Management,&quot; <i>Ther Adv Musculoskelet Dis</i>, 2012, 4(2):111-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/22870499/pubmed\" target=\"_blank\" id=\"22870499\">22870499</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clark CM Jr and Lee DA, &ldquo;Prevention and Treatment of the Complications of Diabetes Mellitus,&rdquo; <i>N Engl J Med</i>, 1995, 332(18):1201-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/7700316/pubmed\" target=\"_blank\" id=\"7700316\">7700316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dagogo-Jack S and Santiago JV, &ldquo;Pathophysiology of Type 2 Diabetes and Modes of Action of Therapeutic Interventions,&rdquo; <i>Arch Intern Med</i>, 1997, 157(16):1802-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/9290539/pubmed\" target=\"_blank\" id=\"9290539\">9290539</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Denus S and Spinler SA, &ldquo;Early Statin Therapy for Acute Coronary Syndromes,&rdquo; <i>Ann Pharmacother</i>, 2002, 36(11):1749-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/12398573/pubmed\" target=\"_blank\" id=\"12398573\">12398573</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Lemos JA, Blazing MA, Wiviott SD, et al, &ldquo;Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes: Phase Z of the A to Z Trial,&rdquo; <i>JAMA</i>, 2004, 292(11):1307-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/15337732/pubmed\" target=\"_blank\" id=\"15337732\">15337732</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fernandez AB, Karas RH, Alsheikh-Ali AA, et al, &ldquo;Statins and Interstitial Lung Disease: A Systematic Review of the Literature and of Food and Drug Administration Adverse Event Reports,&rdquo; <i>Chest</i>, 2008, 134(4):824-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/18689579/pubmed\" target=\"_blank\" id=\"18689579\">18689579</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo; <i>Circulation</i>, 2012, 126(25):3097-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/23166211/pubmed\" target=\"_blank\" id=\"23166211\">23166211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;130(24):e278-e333.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/25085961/pubmed\" target=\"_blank\" id=\"25085961\">25085961</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flolipid (simvastatin) [prescribing information]. Brooksville, FL: Salerno Pharmaceuticals; October 2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/25085961/pubmed\" target=\"_blank\" id=\"25085961\">25085961</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fonarow GC, French WJ, Parsons LS, et al, &ldquo;Use of Lipid-Lowering Medications at Discharge in Patients With Acute Myocardial Infarction: Data From the National Registry of Myocardial Infarction 3,&rdquo; <i>Circulation</i>, 2001, 103(1):38-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/11136683/pubmed\" target=\"_blank\" id=\"11136683\">11136683</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gaster B and Hirsch IB, &ldquo;The Effects of Improved Glycemic Control on Complications in Type 2 Diabetes,&rdquo; <i>Arch Intern Med</i>, 1998, 158(2):134-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/9448551/pubmed\" target=\"_blank\" id=\"9448551\">9448551</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Godfrey LM, Erramouspe J, and Cleveland KW, &quot;Teratogenic Risk of Statins in Pregnancy,&quot; <i>Ann Pharmacother</i>, 2012, 46(10):1419-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/23032657/pubmed\" target=\"_blank\" id=\"23032657\">23032657</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haffner SM, Alexander CM, Cook TJ, et al, &ldquo;Reduced Coronary Events in Simvastatin-Treated Patients With Coronary Heart Disease and Diabetes or Impaired Fasting Glucose Levels: Subgroup Analyses in the Scandinavian Simvastatin Survival Study,&rdquo; <i>Arch Intern Med</i>, 1999, 159(22):2661-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/10597756/pubmed\" target=\"_blank\" id=\"10597756\">10597756</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heeschen C, Hamm CW, Laufs U, et al, &ldquo;Withdrawal of Statins Increases Event Rates in Patients With Acute Coronary Syndromes,&rdquo; <i>Circulation</i>, 2002, 105(12):1446-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/11914253/pubmed\" target=\"_blank\" id=\"11914253\">11914253</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines [published corrections appear in <i>Circulation</i>. 2011;124(25):e956; <i>Circulation</i>. 2012;126(7):e105]. <i>Circulation</i>. 2011;124(23):2610-2642.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/22064600/pubmed\" target=\"_blank\" id=\"22064600\">22064600</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Huang CY, Chung SD, Kao LT, Lin HC, Wang LH. Statin use is associated with bladder pain syndrome/interstitial cystitis: a population-based case-control study. <i>Urol Int</i>. 2015;95(2):227-232.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/26184102/pubmed\" target=\"_blank\" id=\"26184102\">26184102</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. <i>J Clin Lipidol</i>. 2015;9(2):129-169. doi: 10.1016/j.jacl.2015.02.003.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/25911072/pubmed\" target=\"_blank\" id=\"25911072\">25911072</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/24682347/pubmed\" target=\"_blank\" id=\"24682347\">24682347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. <i>Endocr Pract</i>. 2017;23(suppl 2):1-87. doi: 10.4158/EP171764.APPGL.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/28437620/pubmed\" target=\"_blank\" id=\"28437620\">28437620</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24788967\"></a>Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [published correction appears in <i>Stroke</i>. 2015;46(2):e54]. <i>Stroke</i>. 2014;45(7):2160-2236. doi: 10.1161/STR.0000000000000024.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/24788967/pubmed\" target=\"_blank\" id=\"24788967\">24788967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kulik A, Ruel M, Jneid H, et al; American Heart Association Council on Cardiovascular Surgery and Anesthesia. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;131(10):927-964.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/25679302/pubmed\" target=\"_blank\" id=\"25679302\">25679302</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lapi F, Gallo E, Bernasconi S, et al. Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products. <i>Br J Clin Pharmacol</i>. 2008;66(4):572-574.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/18637891/pubmed\" target=\"_blank\" id=\"18637891\">18637891</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    LaRosa JC, Grundy SM, Waters DD, et al, &ldquo;Intensive Lipid Lowering With Atorvastatin in Patients With Stable Coronary Disease,&rdquo; <i>N Engl J Med</i>, 2005, 352(14):1425-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/15755765/pubmed\" target=\"_blank\" id=\"15755765\">15755765</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lecarpentier E, Morel O, Fournier T, et al, &quot;Statins and Pregnancy: Between Supposed Risks and Theoretical Benefits,&quot; <i>Drugs</i>, 2012, 72(6):773-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/22480340/pubmed\" target=\"_blank\" id=\"22480340\">22480340</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    LeManach Y, Godet G, Coriat P, et al, &ldquo;The Impact of Postoperative Discontinuation or Continuation of Chronic Statin Therapy on Cardiac Outcome After Major Vascular Surgery,&rdquo; <i>Anesth Analg</i>, 2007, 104(6):1326-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/17513620/pubmed\" target=\"_blank\" id=\"17513620\">17513620</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McPherson R, Frohlich J, Fodor G, et al, &ldquo;Canadian Cardiovascular Society Position Statement--Recommendations for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease,&rdquo; [published correction appears in <i>Can J Cardiol</i>. 2006, 22(12):1077]. <i>Can J Cardiol</i>. 2006;22(11):913-927.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/16971976/pubmed\" target=\"_blank\" id=\"16971976\">16971976</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;MRC/BHF Heart Protection Study of Cholesterol Lowering With Simvastatin in 20,536 High-Risk Individuals: A Randomised Placebo-Controlled Trial. Heart Protection Study Collaborative Group,&rdquo; <i>Lancet</i>, 2002, 360(9326):7-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/12114036/pubmed\" target=\"_blank\" id=\"12114036\">12114036</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al, &ldquo;ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins,&rdquo; Stroke, 2002, 33(9):2337-41. Available at http://stroke.ahajournals.org/cgi/content/short/33/9/233712215610</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pearson TA, Mensah GA, Alexander RW, et al, &ldquo;Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association,&rdquo; <i>Circulation</i>, 2003, 107(3):499-511.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/12551878/pubmed\" target=\"_blank\" id=\"12551878\">12551878</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peto R, Emberson J, Landray M, et al, &ldquo;Analysis of Cancer Data From Three Ezetimibe Trials,&rdquo; <i>N Engl J Med</i>, 2008, 359(13):1357-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/18765432/pubmed\" target=\"_blank\" id=\"18765432\">18765432</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips BG, Yim JM, Brown EJ Jr, et al, &ldquo;Pharmacologic Profile of Survivors of Acute Myocardial Infarction at United States Academic Hospitals,&rdquo; <i>Am Heart J</i>, 1996, 131(5):872-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/8615304/pubmed\" target=\"_blank\" id=\"8615304\">8615304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Poldermans D, Bax JJ, Kertai MD, et al, &ldquo;Statins Are Associated With a Reduced Incidence of Perioperative Mortality in Patients Undergoing Major Noncardiac Vascular Surgery,&rdquo; <i>Circulation</i>, 2003, 107(14):1848-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/12695283/pubmed\" target=\"_blank\" id=\"12695283\">12695283</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ray KK and Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. <i>J Am Coll Cardiol</i>. 2005;8(46):1425-1433.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/16226165/pubmed\" target=\"_blank\" id=\"16226165\">16226165</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ridker PM, Danielson E, Fonseca FAH, et al, &ldquo;Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein,&rdquo; <i>N Engl J Med</i>, 2008, 359:2195-2207.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/18997196/pubmed\" target=\"_blank\" id=\"18997196\">18997196</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rossebo AB, Pederson TR, Boman K, et al, &ldquo;Intensive Lipid Lowering With Simvastatin and Ezetimibe in Aortic Stenosis,&rdquo; <i>N Engl J Med</i>, 2008, 359(13):1343-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/18765433 /pubmed\" target=\"_blank\" id=\"18765433 \">18765433 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scandinavian Simvastatin Survival Study, &ldquo;Randomized Trial of Cholesterol Lowering in 4444 Patients With Coronary Heart Disease: The Scandinavian Simvastatin Survival Study (4S),&rdquo; <i>Lancet</i>, 1994, 344(8934):1383-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/7968073/pubmed\" target=\"_blank\" id=\"7968073\">7968073</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sever PS, Dahlof B, Poulter NR, et al, &ldquo;Prevention of Coronary and Stroke Events With Atorvastatin in Hypertensive Patients Who Have Average or Lower-Than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial,&rdquo; <i>Lancet</i>, 2003, 361(9364):1149-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/12686036/pubmed\" target=\"_blank\" id=\"12686036\">12686036</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shepherd J, Cobbe SM, Ford I, et al, &ldquo;Prevention of Coronary Heart Disease With Pravastatin in Men With Hypercholesterolemia. West of Scotland Coronary Prevention Study Group,&rdquo; <i>N Engl J Med</i>, 1995, 333(20):1301-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/7566020/pubmed\" target=\"_blank\" id=\"7566020\">7566020</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith DJ, Olive KE. Chinese red rice-induced myopathy. <i>South Med J</i>. 2003;96(12):1265-1267.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/14696880/pubmed\" target=\"_blank\" id=\"14696880\">14696880</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stone NJ, Robinson J, Lichtenstein AH, et al, 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published online ahead of print November 12, 2013].<i>Circulation</i>. 2013; doi: 10.1161/01.cir.0000437738.63853.7a.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, &quot;Intensive Lowering of LDL Cholesterol With 80 mg versus 20 mg Simvastatin Daily in 12,064 Survivors of Myocardial Infarction: A Double-Blind Randomised Trial,&quot; <i>Lancet</i>, 2010, 376(9753):1658-69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/21067805/pubmed\" target=\"_blank\" id=\"21067805\">21067805</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tonelli M, Wanner C; for the Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid Management in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2013 Clinical Practice Guideline [published online ahead of print]. <i>Ann Intern Med</i>. 2013.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/24323134/pubmed\" target=\"_blank\" id=\"24323134\">24323134</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tuccori M, Lapi F, Testi A, et al. Drug-induced taste and smell alterations: a case/non-case evaluation of an italian database of spontaneous adverse drug reaction reporting. <i>Drug Saf</i>. 2011;34(10):849-859.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/21879779/pubmed\" target=\"_blank\" id=\"21879779\">21879779</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Preventive Services Task Force (USPSTF), Bibbins-Domingo K, Grossman DC, et al. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. <i>JAMA</i>. 2016;316(19):1997-2007.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/27838723/pubmed\" target=\"_blank\" id=\"27838723\">27838723</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/simvastatin-drug-information/abstract-text/17555487/pubmed\" target=\"_blank\" id=\"17555487\">17555487</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zocor (simvastatin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; February 2018.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9923 Version 272.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F221302\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50644108\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F221350\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F221307\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F221328\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F221308\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F221309\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22553685\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F22888200\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F221278\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F221263\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F221282\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F221281\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F50324443\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F221358\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F221270\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F221285\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F221267\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F221344\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F221272\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F221299\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F221274\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F1792946\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F221288\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F802418\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F221276\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F49055596\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F221266\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F221284\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F221287\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F221289\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9923|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=simvastatin-patient-drug-information\" class=\"drug drug_patient\">Simvastatin: Patient drug information</a></li><li><a href=\"topic.htm?path=simvastatin-pediatric-drug-information\" class=\"drug drug_pediatric\">Simvastatin: Pediatric drug information</a></li></ul></div></div>","javascript":null}